- Home
- S vs PTGX Comparison
S vs PTGX Comparison
Compare S & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.1B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | S | PTGX |
|---|---|---|
| Price | $12.69 | $83.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 30 | 10 |
| Target Price | $21.47 | ★ $99.20 |
| AVG Volume (30 Days) | ★ 8.7M | 826.0K |
| Earning Date | 03-11-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $955,646,000.00 | $209,217,000.00 |
| Revenue This Year | $24.53 | N/A |
| Revenue Next Year | $20.04 | $409.41 |
| P/E Ratio | ★ N/A | $117.31 |
| Revenue Growth | ★ 24.09 | N/A |
| 52 Week Low | $12.64 | $33.70 |
| 52 Week High | $25.24 | $96.54 |
Technical Indicators
Market Signals| Indicator | S | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 49.06 |
| Support Level | $12.70 | $80.20 |
| Resistance Level | $13.72 | $86.10 |
| Average True Range (ATR) | 0.67 | 3.47 |
| MACD | -0.12 | 0.22 |
| Stochastic Oscillator | 0.37 | 64.58 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.